LAUSANNE, Switzerland--(BUSINESS WIRE)--Nestlé Skin Health today announced organizational changes at top management level to support the company’s expanded market opportunity and ambition. “Our goal is to grow the number of people the company serves to over a billion within 10 years, by offering skin health solutions that protect, maintain, nourish and enhance skin health and, when skin health is compromised, treat, correct and restore the skin to its healthy state,” said Humberto C. Antunes, CEO of Nestlé Skin Health S.A. and Chairman of the Board of Galderma Pharma S.A. “We are focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails.”
Galderma will continue to partner with healthcare professionals around the world to provide innovative medical solutions in dermatology, while a Consumer Skin Health business has been created to focus on meeting skin health needs in the broader market place worldwide.
Stuart Raetzman is appointed CEO of Galderma Pharma S.A. which includes Prescription, Self-medication and Aesthetic & Corrective medical solutions. “Our unique focus on the skin clearly positions us as leaders in the dermatology market and this is set to continue,” said Stuart Raetzman.
Albert Draaijer, formerly Senior Vice President Markets & Franchises at Galderma, is appointed Senior Vice President, Consumer Skin Health. “With this new structure, our existing brands, such as Cetaphil and Daylong, we will find new channels and reach even more consumers, while allowing us to develop new science-based solutions for people around the world,” commented Albert Draaijer.
To support Nestlé Skin Health’s ambition, the following changes were announced:
Janusz Czernielewski, formerly Vice President, Medical Affairs at Galderma, is appointed Vice President, Medical Affairs of Nestlé Skin Health.
Cécile Dussart, formerly Vice President, Manufacturing and Technical Operations at Galderma, is appointed Vice President, Manufacturing and Technical Operations of Nestlé Skin Health.
Alain Jacot, formerly Vice President, Scientific Division at Galderma, is appointed Vice President, Scientific Division of Nestlé Skin Health.
Alain Kirsch, formerly Vice President, Human Resources at Galderma, is appointed Vice President, Human Resources of Nestlé Skin Health.
Torsten Koster, formerly Head of Finance & Control at Nestlé Nespresso S. A., is appointed Chief Financial Officer of Nestlé Skin Health.
Christian Matton, formerly Vice President, Corporate General Counsel at Galderma, is appointed Vice President, Corporate General Counsel of Nestlé Skin Health.
Peter Nicholson, formerly Senior Director, Business Development at Galderma, is appointed Vice President, Business Development & Strategy of Nestlé Skin Health.
About Nestlé Skin Health
Based in Lausanne, Switzerland, Nestlé Skin Health is a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails.
For more information, visit www.nestleskinhealth.com.
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 34 wholly-owned affiliates with a worldwide network of distributors and more than 5,500 employees. Galderma’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
The company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and six manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic brands include Epiduo, Oracea, Differin, Mirvaso, Soolantra, Tri-Luma, Loceryl, Cetaphil, Excipial, Daylong, Metvix, Azzalure, Dysport, Restylane and Emervel. All trademarks are proprietary.
For more information, visit www.galderma.com.